H J KUH
Overview
Explore the profile of H J KUH including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park H, KUH H, Chung S, Lee M, Shim C
Arch Pharm Res
. 2002 Jan;
24(6):584-9.
PMID: 11794540
Isopropryl 2-(1-3-dithiethane-2-ylidene)-2[N-(4-methyl-thiazole-2-yl) carbamoyl] acetate (YH439) is currently under phase II clinical trials by the Yuhan Research Center for use as a hepatoprotective agent. Unfortunately, the oral bioavailbility of YH439, which...
2.
KUH H, Nakagawa S, Usuda J, Yamaoka K, Saijo N, Nishio K
Jpn J Cancer Res
. 2000 Dec;
91(12):1303-13.
PMID: 11123430
Most anticancer agents induce cell cycle arrest (cytostatic effect) and cell death (cytotoxic effect), resulting in the inhibition of population growth of cancer cells. When asynchronous cells are to be...
3.
KUH H, Jang S, Wientjes M, Au J
J Pharmacol Exp Ther
. 2000 Jun;
293(3):761-70.
PMID: 10869374
The intracellular pharmacokinetics of paclitaxel is closely related to its pharmacodynamics. Although drug transport across the cell membrane and extracellular and intracellular drug binding have been shown to affect intracellular...
4.
Fukumoto H, Tamura T, Kamiya Y, Usuda J, Suzuki T, Kanzawa F, et al.
Invest New Drugs
. 2000 Apr;
17(4):335-41.
PMID: 10759401
7-hydroxystaurosporine (UCN-01) is a new anticancer agent which exerts an inhibitory effect on cell cycle check points and is currently under phase I clinical trials in US and Japan. Preliminary...
5.
Suzuki T, Sasaki H, KUH H, Agui M, Tatsumi Y, Tanabe S, et al.
Gene
. 2000 Mar;
242(1-2):167-73.
PMID: 10721709
The multidrug-resistant phenotype in tumor cells is attributed in part to anti-cancer drug efflux transporters such as the MRP family. The amino-terminal structure of MRP5 has not been refined. To...
6.
Usuda J, Saijo N, Fukuoka K, Fukumoto H, KUH H, Nakamura T, et al.
Int J Cancer
. 2000 Jan;
85(2):275-80.
PMID: 10629089
UCN-01 (7-hydroxystaurosporine) inhibits the growth of various malignant cell lines in vitro and in vivo. In this study, a human small cell lung carcinoma subline resistant to UCN-01, SBC-3/UCN, was...
7.
KUH H, Jang S, Wientjes M, Weaver J, Au J
J Pharmacol Exp Ther
. 1999 Jul;
290(2):871-80.
PMID: 10411604
The present study examined the determinants of the penetration and accumulation of [(3)H]paclitaxel (12-12,000 nM) in three-dimensional histocultures of patient tumors and of a human xenograft tumor in mice. The...
8.
Au J, Li D, Gan Y, Gao X, Johnson A, Johnston J, et al.
Cancer Res
. 1998 May;
58(10):2141-8.
PMID: 9605758
The kinetics of the time-dependent antitumor effects of paclitaxel are not fully understood; some literature reports indicate a higher activity by prolonging treatment durations, whereas other reports indicate no enhancement...
9.
KUH H, Shim C
Arch Pharm Res
. 1994 Apr;
17(2):124-30.
PMID: 10319144
Plasma pharmacokinetics and renal excretion of theophylline (TP) and its metabolites were investigated in rats. Plasma concentrations of TP declined in a monoexponential manner, while those of 1-methyluric (MU) and...
10.
MAYALL R, Barbosa C, BRUM F, KUH H
J Cardiovasc Surg (Torino)
. 1964 Nov;
5:732-5.
PMID: 14242830
No abstract available.